Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this ...

The complement proteins C3 and protease factor B have a central role in the activation pathways of the complement system. Recent advances in the structural biology of complement protein C3 ...

Sitala Bio Ltd. has prepared new indole derivatives acting as complement factor B (CFB) inhibitors. They are thus reported to be useful for the treatment of age-related macular degeneration, ...

The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3 ...

The FDA Wednesday granted an accelerated approval to Novartis’ Fabhalta in IgAN. The complement factor B inhibitor, plus the endothelin A receptor antagonist atrasentan and the anti-APRIL ...

LAS VEGAS, April 29, 2025 /PRNewswire/ -- DelveInsight's "FABHALTA Market Size, Forecast, and Market Insight Report" highlights the details around FABHALTA, an oral complement factor B inhibitor ...